Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

Michael S. Mathisen, Hagop M. Kantarjian, Jorge Cortes, Elias J. Jabbour

Research output: Contribution to journalReview article

Abstract

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients as well as those who fail imatinib. Bosutinib and ponatinib have also become available as second line options. With five agents from which to choose, selecting a TKI has become a challenge. Multiple tests are now available to determine a patient's disease status, making the ideal monitoring strategy unclear. The gold standard for response to TKI therapy remains the achievement of complete cytogenetic response. This review will discuss the practical aspects of selecting a TKI and monitoring a patient once on therapy, including when to consider a treatment change. Other relevant issues, including cost, compliance, role of allogeneic hematopoietic cell transplantation, and discontinuation of TKIs will also be covered.

Original languageEnglish (US)
Pages (from-to)179-187
Number of pages9
JournalBlood Reviews
Volume28
Issue number5
DOIs
StatePublished - Sep 2014
Externally publishedYes

Fingerprint

Explosions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cell Transplantation
Physiologic Monitoring
Standard of Care
Cytogenetics
Compliance
Therapeutics
Costs and Cost Analysis

Keywords

  • Bosutinib
  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Nilotinib
  • Ponatinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. / Mathisen, Michael S.; Kantarjian, Hagop M.; Cortes, Jorge; Jabbour, Elias J.

In: Blood Reviews, Vol. 28, No. 5, 09.2014, p. 179-187.

Research output: Contribution to journalReview article

Mathisen, Michael S. ; Kantarjian, Hagop M. ; Cortes, Jorge ; Jabbour, Elias J. / Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. In: Blood Reviews. 2014 ; Vol. 28, No. 5. pp. 179-187.
@article{837b0a55dcf94e54ae02da6d51ce92df,
title = "Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia",
abstract = "The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients as well as those who fail imatinib. Bosutinib and ponatinib have also become available as second line options. With five agents from which to choose, selecting a TKI has become a challenge. Multiple tests are now available to determine a patient's disease status, making the ideal monitoring strategy unclear. The gold standard for response to TKI therapy remains the achievement of complete cytogenetic response. This review will discuss the practical aspects of selecting a TKI and monitoring a patient once on therapy, including when to consider a treatment change. Other relevant issues, including cost, compliance, role of allogeneic hematopoietic cell transplantation, and discontinuation of TKIs will also be covered.",
keywords = "Bosutinib, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, Ponatinib, Tyrosine kinase inhibitors",
author = "Mathisen, {Michael S.} and Kantarjian, {Hagop M.} and Jorge Cortes and Jabbour, {Elias J.}",
year = "2014",
month = "9",
doi = "10.1016/j.blre.2014.06.001",
language = "English (US)",
volume = "28",
pages = "179--187",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

AU - Mathisen, Michael S.

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge

AU - Jabbour, Elias J.

PY - 2014/9

Y1 - 2014/9

N2 - The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients as well as those who fail imatinib. Bosutinib and ponatinib have also become available as second line options. With five agents from which to choose, selecting a TKI has become a challenge. Multiple tests are now available to determine a patient's disease status, making the ideal monitoring strategy unclear. The gold standard for response to TKI therapy remains the achievement of complete cytogenetic response. This review will discuss the practical aspects of selecting a TKI and monitoring a patient once on therapy, including when to consider a treatment change. Other relevant issues, including cost, compliance, role of allogeneic hematopoietic cell transplantation, and discontinuation of TKIs will also be covered.

AB - The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients as well as those who fail imatinib. Bosutinib and ponatinib have also become available as second line options. With five agents from which to choose, selecting a TKI has become a challenge. Multiple tests are now available to determine a patient's disease status, making the ideal monitoring strategy unclear. The gold standard for response to TKI therapy remains the achievement of complete cytogenetic response. This review will discuss the practical aspects of selecting a TKI and monitoring a patient once on therapy, including when to consider a treatment change. Other relevant issues, including cost, compliance, role of allogeneic hematopoietic cell transplantation, and discontinuation of TKIs will also be covered.

KW - Bosutinib

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Imatinib

KW - Nilotinib

KW - Ponatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84906937473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906937473&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2014.06.001

DO - 10.1016/j.blre.2014.06.001

M3 - Review article

C2 - 24984571

AN - SCOPUS:84906937473

VL - 28

SP - 179

EP - 187

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 5

ER -